A5087998826- Neuroinflammation and Neurodegeneration Mechanisms
- Alzheimer's disease research and treatments
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Estrogen and related hormone effects
- Cancer-related molecular mechanisms research
- Single-cell and spatial transcriptomics
- Neurological Disease Mechanisms and Treatments
Baylor College of Medicine
2021-2025
Genetic studies of Alzheimer disease (AD) have prioritized variants in genes related to the amyloid cascade, lipid metabolism, and neuroimmune modulation. However, cell-specific effect these is not fully understood. Here, we perform single-nucleus RNA-sequencing (snRNA-seq) on nearly 300,000 nuclei from parietal cortex AD autosomal dominant (APP PSEN1) risk-modifying variant (APOE, TREM2 MS4A) carriers. Within individual cell types, capture commonly dysregulated across groups. specific...
Abstract Background: Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone and HER2 expression, represents an aggressive subtype with poor prognosis due to limited therapeutic options beyond chemotherapy. Current molecular subtyping methods fail predict outcomes despite known tumor-immune-stromal interactions. The tumor microenvironment (TME) influences treatment resistance, yet capturing its complex dynamics remains challenging. TNBC demonstrates...
Abstract Background Alzheimer disease (AD) has substantial genetic, molecular, and cellular heterogeneity associated with its etiology. Much of our current understanding the main AD molecular events amyloid hypothesis ( APP, PSEN1 PSEN2 ) neuroimmune modulation TREM2 MS4A is based on genetic studies including GWAS. However, functional genes, downstream transcriptional ramifications, cell-type-specific effects many GWAS loci remain poorly understood. Understanding these can point us to...
Abstract Tumor heterogeneity presents a major challenge in the clinical management of breast cancers by impacting patient’s prognosis, therapeutic response, and outcomes. Triple-negative cancer (TNBC) carries worst prognosis among all intrinsic subtypes has limited treatment options. Currently, TNBC are mainly refined into four categories: basal-like (BL1 BL2), luminal androgen receptor (LAR) mesenchymal (M). Although each these tumor-specific represent different gene expression profiles,...